Table 1 Correlation between the presence of NDRG4-SPR methylation and well-established prognostic factors in 61 patients with breast invasive ductal carcinoma
Parameters | NDRG4 promoter status | |||
|---|---|---|---|---|
Meth (%) | Unmeth (%) | p | ||
Age of patient (y) | <=40 | 8 (72.7) | 3 (27.3%) | |
>40 | 43 (86%) | 7 (14%) | 0.367 | |
Grade | 1 | 7 (87.5%) | 1 (12.5%) | |
2 | 31 (91.2%) | 3 (8.8%) | ||
3 | 13 (68.4%) | 6 (31.6%) | 0.095 | |
SBR grade | 1 | 13 (86.7%) | 2 (13.3%) | |
2 | 29 (80.6%) | 7 (19.4%) | ||
3 | 8 (100%) | 0 | 0.373 | |
Lymph node | 0 | 23 (88.5%) | 3 (11.5%) | |
involvement | 1–3 | 18 (94.7%) | 1 (5.3%) | |
>4 | 10 (62.5%) | 6 (37.5%) | 0.025 | |
ER | Neg | 18 (81.8%) | 4 (18.2%) | |
Pos | 33 (84.6%) | 6 (15.4%) | 1 | |
PR | Neg | 35 (85.4%) | 6 (14.6%) | |
Pos | 16 (80%) | 4 (20%) | 0.716 | |
p53 | Neg | 38 (92.7%) | 3 (7.3%) | |
Pos | 11 (64.7%) | 6 (35.3%) | 0.014 | |
Initial tumor size | <2 | 18 (94.7%) | 1 (5.3%) | |
(cm) | 2–5 | 30 (83.3%) | 6 (16.7%) | |
>5 | 3 (50%) | 3 (50%) | 0.036 | |
Lymphatic | Neg | 15 (93.8%) | 1 (6.3%) | |
Invasion | Pos | 24 (72.7%) | 9 (27.3%) | 0.199 |
Perineural | Neg | 30 (85.7%) | 5 (14.3%) | |
Invasion | Pos | 17 (77.3%) | 5 (22.7%) | |
